Testicular Cancer

Robot-Assisted Transmesocolic Retroperitoneal Lymphadenectomy in Testicular Non-Seminomatous Germ Cell Tumors: A Promising Approach.

Testicular cancer accounts for 5% of urological tumors, with an incidence of 5.6 cases per 100,000 men per year in Europe (1). Salvage retroperitoneal lymphadenectomy is the standard surgery for persistent retroperitoneal masses after chemotherapy.

Elevations of α-fetoprotein in patients undergoing chemotherapy for pure testicular seminoma: a retrospective cohort study.

α-Fetoprotein (AFP) is conventionally absent in testicular classical seminoma (TCS). However, moderate AFP elevations can occur in TCS patients, as observed at this and other centres, which can be challenging to diagnostic and management practices.

Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review.

To conduct a systematic review of the current literature to determine the current role of primary retroperitoneal lymph node dissection (RPLND) in stage II testicular seminoma and its associated oncological, functional and peri-operative outcomes.

Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends Survey.

The 2021 updated International Germ Cell Cancer Collaborative Group classification for seminomatous germ cell tumours confirmed and refined the original classification, introducing the notion that lactate dehydrogenase (LDH) elevation above 2.

Prediction Model for Brain Metastasis in Patients With Metastatic Germ-Cell Tumors.

Brain metastasis (BM) is an independent adverse prognostic factor in metastatic germ cell tumors (mGCT). We aimed to establish an effective and practical BM prediction model.

Between January 1990 and September 2017, 2291 patients with mGCT who were treated at Indiana University were identified.

Analysis of a mouse germ cell tumor model establishes pluripotency-associated miRNAs as conserved serum biomarkers for germ cell cancer detection.

Malignant testicular germ cells tumors (TGCTs) are the most common solid cancers in young men. Current TGCT diagnostics include conventional serum protein markers, but these lack the sensitivity and specificity to serve as accurate markers across all TGCT subtypes.

Biochemical Hypogonadism in Aging Testicular Cancer Survivors: A Clinical Challenge.

Few longitudinal studies have described the prevalence and development of biochemical hypogonadism in aging testicular cancer survivors (TCSs) in comparison to men from the general population (control subjects).

Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer.

To comprehensively evaluate the longitudinal progression of cumulative burden of morbidity (CBM) in testicular cancer survivors (TCS) following standard-dose cisplatin-chemotherapy and the impact of modifiable risk factors on morbidity and early-mortality.

Testicular Germ Cell Tumors: A Review.

Testicular cancer is the most common solid malignancy among males aged 15 to 40 years in the US, with approximately 10 000 new cases diagnosed each year. Between 90% and 95% of testicular cancers are germ cell tumors (GCTs).

Long-Term Relapse and Survival in Clinical Stage I Testicular Teratoma - Beyond the Abstract

Pure testicular teratomas comprise 4-9% of all testicular tumors, with teratomatous elements present in approximately 50% of mixed germ cell tumors (GCTs). The natural history of CS I non-seminomatous germ cell tumors (NSGCT) managed with surveillance has been well studied. However, there is a significant knowledge gap in characterizing oncologic outcomes of patients diagnosed with CS I pure teratoma.